US20070020186A1 - Solid dosage formulations of narcotic drugs having improved buccal adsorption - Google Patents
Solid dosage formulations of narcotic drugs having improved buccal adsorption Download PDFInfo
- Publication number
- US20070020186A1 US20070020186A1 US11/186,925 US18692505A US2007020186A1 US 20070020186 A1 US20070020186 A1 US 20070020186A1 US 18692505 A US18692505 A US 18692505A US 2007020186 A1 US2007020186 A1 US 2007020186A1
- Authority
- US
- United States
- Prior art keywords
- solid dosage
- fentanyl
- formulations according
- dosage formulations
- narcotic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Definitions
- the present invention concerns solid dosage formulations of narcotic drugs having improved buccal adsorption.
- the formulations of the invention are characterized by the introduction in a buccal formulation of a soluble organic compound having a primary, secondary or tertiary amine group.
- buccal formulations are more and more popular for drug administrations. They exhibit in fact several advantages in comparison with other solid dosage forms; in particular, buccal formulations dissolve in the oral cavity without requiring water for ingestion, allowing the buccal adsorption of drugs coming into contact with the oral mucosa in dissolved form. Sometimes, buccal administration does not unfortunately always allow to obtain a fast onset of action of the drug, as the result of difficulties of the drug to cross the skin barrier of mucosa and to penetrate into the blood stream.
- the amount of amine required in the formulation ranges between 0.1 to 500% of the moles of active component(s), more preferably 0.5 to 300% and most preferably 1 to 200%.
- amines used in order to improve bioavailability according to the invention include Histidine, Arginine, Lysine, Triethanolamine, Trimethylamine, Betaine, Pyrrolidine, Guanidine, Cysteamine, Taurine and derivatives and analogues thereof.
- Arginine is a preferred non-toxic amine.
- Oral dispersible tablets containing 200 mcg of Fentanyl were obtained as follows:
- a pharmacokinetic study was carried out on 6 fasting healthy volunteers treated with a buccal formulation prepared in accordance with example # 1A containing 200 mcg of Fentanyl. The results were compared with a pharmacokinetic study carried out on 6 healthy volunteers treated with a buccal formulation prepared in accordance with example # 1B containing 400 mcg of Fentanyl.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Anesthesiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (28)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/186,925 US20070020186A1 (en) | 2005-07-22 | 2005-07-22 | Solid dosage formulations of narcotic drugs having improved buccal adsorption |
MX2007015480A MX2007015480A (es) | 2005-07-22 | 2006-07-21 | Formulaciones de dosificacion solida de medicamentos narcoticos que tienen adsorcion bucal mejorada. |
CA2607360A CA2607360C (en) | 2005-07-22 | 2006-07-21 | Solid dosage formulations of narcotic drugs having improved buccal adsorption |
PL06776336T PL1906961T3 (pl) | 2005-07-22 | 2006-07-21 | Stałe preparaty do dawkowania fentanylu o zwiększonym wchłanianiu dopoliczkowym |
EP06776336.7A EP1906961B1 (en) | 2005-07-22 | 2006-07-21 | Solid dosage formulations of fentanyl having improved buccal adsorption |
TW095126670A TW200727922A (en) | 2005-07-22 | 2006-07-21 | Solid dosage formulations of narcotic drugs having improved buccal adsorption |
AU2006271870A AU2006271870B2 (en) | 2005-07-22 | 2006-07-21 | Solid dosage formulations of narcotic drugs having improved buccal adsorption |
DK06776336.7T DK1906961T3 (en) | 2005-07-22 | 2006-07-21 | FIXED DOSAGE FORMS OF FENTANYL WITH IMPROVED BUCHAL ADSORPTION |
PCT/EP2006/007189 WO2007009806A2 (en) | 2005-07-22 | 2006-07-21 | Solid dosage formulations of narcotic drugs having improved buccal adsorption |
JP2008521904A JP5714797B2 (ja) | 2005-07-22 | 2006-07-21 | 口腔内への吸着の改善された麻酔薬の固形投与製剤 |
RU2007149044/15A RU2408373C2 (ru) | 2005-07-22 | 2006-07-21 | Твердые лекарственные формы наркотических лекарственных средств с улучшенным всасыванием при трансбуккальном введении |
KR1020087000576A KR101326206B1 (ko) | 2005-07-22 | 2006-07-21 | 개선된 구강 흡수성을 갖는 마취성 약물의 고형 복용 제제 |
NZ563511A NZ563511A (en) | 2005-07-22 | 2006-07-21 | Solid dosage formulations of narocotic drugs having improved buccal adsorption |
ES06776336.7T ES2569228T3 (es) | 2005-07-22 | 2006-07-21 | Formulaciones de formas farmacéuticas sólidas de fentanilo que tienen mejor adsorción bucal |
RS20160214A RS54670B1 (en) | 2005-07-22 | 2006-07-21 | SOLID DOSAGE FORMULATION OF FENTANIL WITH IMPROVED BUCHAL ADSORPTION |
SI200632040A SI1906961T1 (sl) | 2005-07-22 | 2006-07-21 | Trdne farmacevtske formulacije fentanila z izboljšano bukalno absorpcijo |
BRPI0613769-5A BRPI0613769A2 (pt) | 2005-07-22 | 2006-07-21 | formulações de dosagem sólidas de fármacos narcóticos tendo adsorção bucal aperfeiçoada |
CNA2006800232888A CN101208091A (zh) | 2005-07-22 | 2006-07-21 | 促进口腔吸收的麻醉药的固体药制剂 |
HUE06776336A HUE027354T2 (en) | 2005-07-22 | 2006-07-21 | Dosage forms containing fentanyl with improved buccal adsorption |
UAA200713973A UA90518C2 (ru) | 2005-07-22 | 2006-07-21 | Фармацевтическая композиция в форме таблетки, которая имеет улучшеное всасывание при трансбукальном введение, которая содержит наркотический активный ингредиент и амин |
US11/490,500 US8574552B2 (en) | 2005-07-22 | 2006-07-21 | Solid dosage formulations of narcotic drugs having improved buccal adsorption |
IL187387A IL187387A (en) | 2005-07-22 | 2007-11-15 | Composition for solid doses of narcotic drugs with enhanced absorption from the cheek |
ZA200710406A ZA200710406B (en) | 2005-07-22 | 2007-11-30 | Solid dosage formulations of narcotic drugs having improved buccal absorption |
NO20080827A NO20080827L (no) | 2005-07-22 | 2008-02-15 | Faste doseringsformuleringer av narkotiske legemidler som har forbedret bukal adsorpsjon |
MA30659A MA29744B1 (fr) | 2005-07-22 | 2008-02-18 | Formulations posologiques solides de medicaments presentant une adsorption buccale amelioree |
US14/017,642 US10258693B2 (en) | 2005-07-22 | 2013-09-04 | Solid dosage formulations of narcotic drugs having improved buccal adsorption |
HRP20160327TT HRP20160327T1 (hr) | 2005-07-22 | 2016-04-01 | Čvrsti dozirni oblici fentanila s poboljšanom bukalnom apsorpcijom |
CY20161100346T CY1117470T1 (el) | 2005-07-22 | 2016-04-26 | Στερεα δοσολογικα σκευασματα με βελτιωμενη ενδοστοματικη προσροφηση |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/186,925 US20070020186A1 (en) | 2005-07-22 | 2005-07-22 | Solid dosage formulations of narcotic drugs having improved buccal adsorption |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/490,500 Continuation-In-Part US8574552B2 (en) | 2005-07-22 | 2006-07-21 | Solid dosage formulations of narcotic drugs having improved buccal adsorption |
Publications (1)
Publication Number | Publication Date |
---|---|
US20070020186A1 true US20070020186A1 (en) | 2007-01-25 |
Family
ID=37440618
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/186,925 Abandoned US20070020186A1 (en) | 2005-07-22 | 2005-07-22 | Solid dosage formulations of narcotic drugs having improved buccal adsorption |
US11/490,500 Active 2028-10-01 US8574552B2 (en) | 2005-07-22 | 2006-07-21 | Solid dosage formulations of narcotic drugs having improved buccal adsorption |
US14/017,642 Active US10258693B2 (en) | 2005-07-22 | 2013-09-04 | Solid dosage formulations of narcotic drugs having improved buccal adsorption |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/490,500 Active 2028-10-01 US8574552B2 (en) | 2005-07-22 | 2006-07-21 | Solid dosage formulations of narcotic drugs having improved buccal adsorption |
US14/017,642 Active US10258693B2 (en) | 2005-07-22 | 2013-09-04 | Solid dosage formulations of narcotic drugs having improved buccal adsorption |
Country Status (26)
Country | Link |
---|---|
US (3) | US20070020186A1 (ru) |
EP (1) | EP1906961B1 (ru) |
JP (1) | JP5714797B2 (ru) |
KR (1) | KR101326206B1 (ru) |
CN (1) | CN101208091A (ru) |
AU (1) | AU2006271870B2 (ru) |
BR (1) | BRPI0613769A2 (ru) |
CA (1) | CA2607360C (ru) |
CY (1) | CY1117470T1 (ru) |
DK (1) | DK1906961T3 (ru) |
ES (1) | ES2569228T3 (ru) |
HR (1) | HRP20160327T1 (ru) |
HU (1) | HUE027354T2 (ru) |
IL (1) | IL187387A (ru) |
MA (1) | MA29744B1 (ru) |
MX (1) | MX2007015480A (ru) |
NO (1) | NO20080827L (ru) |
NZ (1) | NZ563511A (ru) |
PL (1) | PL1906961T3 (ru) |
RS (1) | RS54670B1 (ru) |
RU (1) | RU2408373C2 (ru) |
SI (1) | SI1906961T1 (ru) |
TW (1) | TW200727922A (ru) |
UA (1) | UA90518C2 (ru) |
WO (1) | WO2007009806A2 (ru) |
ZA (1) | ZA200710406B (ru) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070207207A1 (en) * | 2006-01-06 | 2007-09-06 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
US20070260491A1 (en) * | 2006-05-08 | 2007-11-08 | Pamela Palmer | System for delivery and monitoring of administration of controlled substances |
US20070299687A1 (en) * | 2006-06-23 | 2007-12-27 | Pamela Palmer | Inpatient system for patient-controlled delivery of oral transmucosal medications dosed as needed |
US20080147044A1 (en) * | 2006-01-06 | 2008-06-19 | Acelrx Pharmaceuticals, Inc. | Methods for administering small volume oral transmucosal dosage forms using a dispensing device |
US20080164275A1 (en) * | 2007-01-05 | 2008-07-10 | Acelrx Pharmaceuticals, Inc. | Storage and dispensing devices for administration of oral transmucosal dosage forms |
US20090131479A1 (en) * | 2006-01-06 | 2009-05-21 | Acelrx Pharmaceuticals, Inc. | Small-volume oral transmucosal dosage |
US8252329B2 (en) | 2007-01-05 | 2012-08-28 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
US8357114B2 (en) | 2006-01-06 | 2013-01-22 | Acelrx Pharmaceuticals, Inc. | Drug dispensing device with flexible push rod |
US8535714B2 (en) | 2006-01-06 | 2013-09-17 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
US8753308B2 (en) | 2006-01-06 | 2014-06-17 | Acelrx Pharmaceuticals, Inc. | Methods for administering small volume oral transmucosal dosage forms using a dispensing device |
US8865743B2 (en) | 2006-01-06 | 2014-10-21 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
US8945592B2 (en) | 2008-11-21 | 2015-02-03 | Acelrx Pharmaceuticals, Inc. | Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same |
US11058856B2 (en) | 2014-12-23 | 2021-07-13 | Acelrx Pharmaceuticals, Inc. | Systems, devices and methods for dispensing oral transmucosal dosage forms |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
US8497258B2 (en) | 2005-11-12 | 2013-07-30 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
BRPI0811319A2 (pt) | 2007-05-25 | 2015-02-10 | Tolmar Therapeutics Inc | Composição fluida, método de formação de uma composição fluida, implante biodegrádavel formado in situ, método de formação de um implante biodegradável in situ, kit, implante e método de trataento |
WO2010144865A2 (en) | 2009-06-12 | 2010-12-16 | Meritage Pharma, Inc. | Methods for treating gastrointestinal disorders |
US9272044B2 (en) | 2010-06-08 | 2016-03-01 | Indivior Uk Limited | Injectable flowable composition buprenorphine |
GB2481017B (en) | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
RU2476209C1 (ru) * | 2012-02-29 | 2013-02-27 | Станислав Анатольевич Кедик | Имплантируемое лекарственное средство на основе налтрексона для лечения пациентов, зависимых от алкоголя или опиатов |
ES2699806T3 (es) | 2012-04-18 | 2019-02-12 | SpecGx LLC | Composiciones farmacéuticas, disuasivas del abuso, de liberación inmediata |
JP6031599B2 (ja) | 2012-07-12 | 2016-11-24 | マリンクロッド エルエルシー | 長期放出性、濫用抑止特性薬学的組成物 |
GB201404139D0 (en) | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
US11478426B2 (en) | 2018-09-25 | 2022-10-25 | SpecGx LLC | Abuse deterrent immediate release capsule dosage forms |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6200604B1 (en) * | 1998-03-27 | 2001-03-13 | Cima Labs Inc. | Sublingual buccal effervescent |
US20020013331A1 (en) * | 2000-06-26 | 2002-01-31 | Williams Robert O. | Methods and compositions for treating pain of the mucous membrane |
US20030082107A1 (en) * | 1997-10-01 | 2003-05-01 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer |
US20030104041A1 (en) * | 1999-12-16 | 2003-06-05 | Tsung-Min Hsu | Transdermal and topical administration of drugs using basic permeation enhancers |
US20030215502A1 (en) * | 2002-03-20 | 2003-11-20 | Elan Pharma International Limited | Fast dissolving dosage forms having reduced friability |
US20040253307A1 (en) * | 2003-02-04 | 2004-12-16 | Brian Hague | Sugar-free oral transmucosal solid dosage forms and uses thereof |
US20050013857A1 (en) * | 2003-05-07 | 2005-01-20 | Yourong Fu | Highly plastic granules for making fast melting tablets |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5785989A (en) | 1985-05-01 | 1998-07-28 | University Utah Research Foundation | Compositions and methods of manufacturing of oral dissolvable medicaments |
US5464632C1 (en) | 1991-07-22 | 2001-02-20 | Prographarm Lab | Rapidly disintegratable multiparticular tablet |
EP0553777B1 (en) | 1992-01-29 | 2002-04-24 | Takeda Chemical Industries, Ltd. | Fast dissolving tablet and its production |
US5576014A (en) | 1994-01-31 | 1996-11-19 | Yamanouchi Pharmaceutical Co., Ltd | Intrabuccally dissolving compressed moldings and production process thereof |
US5888534A (en) | 1995-06-13 | 1999-03-30 | Pentech Pharmaceuticals, Inc. | Controlled release of drugs delivered by sublingual or buccal administration |
US5624677A (en) | 1995-06-13 | 1997-04-29 | Pentech Pharmaceuticals, Inc. | Controlled release of drugs delivered by sublingual or buccal administration |
GB9517062D0 (en) | 1995-08-18 | 1995-10-25 | Scherer Ltd R P | Pharmaceutical compositions |
KR20000022239A (ko) * | 1996-07-11 | 2000-04-25 | 토마스 헤인 | 인돌 선택성 세로토닌 작용약을 함유한 내포 복합체 |
JP3770666B2 (ja) | 1996-09-20 | 2006-04-26 | 株式会社ティ・ティ・エス技術研究所 | 経粘膜吸収製剤用組成物 |
EP0839526A3 (en) | 1996-10-31 | 1999-01-07 | Takeda Chemical Industries, Ltd. | Solid pharmaceutical preparation with fast buccal disintegration or dissolution |
US6024981A (en) | 1997-04-16 | 2000-02-15 | Cima Labs Inc. | Rapidly dissolving robust dosage form |
ATE323467T1 (de) | 1997-07-25 | 2006-05-15 | Alpex Pharma Sa | Verfahren zur herstellung eines granulates, geeignet zur herstellung schnell-freisetzender, im mund löslicher tabletten |
US5869098A (en) | 1997-08-20 | 1999-02-09 | Fuisz Technologies Ltd. | Fast-dissolving comestible units formed under high-speed/high-pressure conditions |
US6350470B1 (en) | 1998-04-29 | 2002-02-26 | Cima Labs Inc. | Effervescent drug delivery system for oral administration |
US6974590B2 (en) | 1998-03-27 | 2005-12-13 | Cima Labs Inc. | Sublingual buccal effervescent |
US6270790B1 (en) | 1998-08-18 | 2001-08-07 | Mxneil-Ppc, Inc. | Soft, convex shaped chewable tablets having reduced friability |
US6680071B1 (en) | 1999-03-03 | 2004-01-20 | R. P. Scherer Technologies, Inc. | Opioid agonist in a fast dispersing dosage form |
JP2000281589A (ja) | 1999-03-26 | 2000-10-10 | T T S Gijutsu Kenkyusho:Kk | 経粘膜吸収助剤 |
US6210699B1 (en) | 1999-04-01 | 2001-04-03 | Watson Pharmaceuticals, Inc. | Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity |
US6264981B1 (en) | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
US6733781B2 (en) | 2000-12-06 | 2004-05-11 | Wyeth | Fast dissolving tablet |
CA2479098A1 (en) * | 2002-03-20 | 2003-09-25 | Maree Therese Smith | Methods and compositions comprising nitric oxide donors and opioid analgesics |
US20040202698A1 (en) | 2003-04-02 | 2004-10-14 | The Procter & Gamble Company | Drug delivery systems comprising an encapsulated active ingredient |
BRPI0418228B8 (pt) * | 2003-12-31 | 2021-05-25 | Cima Labs Inc | forma de dosagem, e, método de preparação de um tablete para administração bucal, gengival ou sublingual de fentanil |
-
2005
- 2005-07-22 US US11/186,925 patent/US20070020186A1/en not_active Abandoned
-
2006
- 2006-07-21 KR KR1020087000576A patent/KR101326206B1/ko active IP Right Grant
- 2006-07-21 WO PCT/EP2006/007189 patent/WO2007009806A2/en active Application Filing
- 2006-07-21 TW TW095126670A patent/TW200727922A/zh unknown
- 2006-07-21 CN CNA2006800232888A patent/CN101208091A/zh active Pending
- 2006-07-21 ES ES06776336.7T patent/ES2569228T3/es active Active
- 2006-07-21 CA CA2607360A patent/CA2607360C/en active Active
- 2006-07-21 PL PL06776336T patent/PL1906961T3/pl unknown
- 2006-07-21 RS RS20160214A patent/RS54670B1/en unknown
- 2006-07-21 NZ NZ563511A patent/NZ563511A/en not_active IP Right Cessation
- 2006-07-21 JP JP2008521904A patent/JP5714797B2/ja active Active
- 2006-07-21 RU RU2007149044/15A patent/RU2408373C2/ru active
- 2006-07-21 HU HUE06776336A patent/HUE027354T2/en unknown
- 2006-07-21 US US11/490,500 patent/US8574552B2/en active Active
- 2006-07-21 UA UAA200713973A patent/UA90518C2/ru unknown
- 2006-07-21 EP EP06776336.7A patent/EP1906961B1/en active Active
- 2006-07-21 DK DK06776336.7T patent/DK1906961T3/en active
- 2006-07-21 BR BRPI0613769-5A patent/BRPI0613769A2/pt not_active Application Discontinuation
- 2006-07-21 SI SI200632040A patent/SI1906961T1/sl unknown
- 2006-07-21 AU AU2006271870A patent/AU2006271870B2/en not_active Ceased
- 2006-07-21 MX MX2007015480A patent/MX2007015480A/es active IP Right Grant
-
2007
- 2007-11-15 IL IL187387A patent/IL187387A/en not_active IP Right Cessation
- 2007-11-30 ZA ZA200710406A patent/ZA200710406B/xx unknown
-
2008
- 2008-02-15 NO NO20080827A patent/NO20080827L/no not_active Application Discontinuation
- 2008-02-18 MA MA30659A patent/MA29744B1/fr unknown
-
2013
- 2013-09-04 US US14/017,642 patent/US10258693B2/en active Active
-
2016
- 2016-04-01 HR HRP20160327TT patent/HRP20160327T1/hr unknown
- 2016-04-26 CY CY20161100346T patent/CY1117470T1/el unknown
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030082107A1 (en) * | 1997-10-01 | 2003-05-01 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer |
US6200604B1 (en) * | 1998-03-27 | 2001-03-13 | Cima Labs Inc. | Sublingual buccal effervescent |
US20030104041A1 (en) * | 1999-12-16 | 2003-06-05 | Tsung-Min Hsu | Transdermal and topical administration of drugs using basic permeation enhancers |
US20020013331A1 (en) * | 2000-06-26 | 2002-01-31 | Williams Robert O. | Methods and compositions for treating pain of the mucous membrane |
US20020192288A1 (en) * | 2000-06-26 | 2002-12-19 | Williams Robert O. | Methods and compositions for treating pain of the mucous membrane |
US20030215502A1 (en) * | 2002-03-20 | 2003-11-20 | Elan Pharma International Limited | Fast dissolving dosage forms having reduced friability |
US20040253307A1 (en) * | 2003-02-04 | 2004-12-16 | Brian Hague | Sugar-free oral transmucosal solid dosage forms and uses thereof |
US20050013857A1 (en) * | 2003-05-07 | 2005-01-20 | Yourong Fu | Highly plastic granules for making fast melting tablets |
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8753308B2 (en) | 2006-01-06 | 2014-06-17 | Acelrx Pharmaceuticals, Inc. | Methods for administering small volume oral transmucosal dosage forms using a dispensing device |
US9289583B2 (en) | 2006-01-06 | 2016-03-22 | Acelrx Pharmaceuticals, Inc. | Methods for administering small volume oral transmucosal dosage forms using a dispensing device |
US20070207207A1 (en) * | 2006-01-06 | 2007-09-06 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
US20080147044A1 (en) * | 2006-01-06 | 2008-06-19 | Acelrx Pharmaceuticals, Inc. | Methods for administering small volume oral transmucosal dosage forms using a dispensing device |
US8778393B2 (en) | 2006-01-06 | 2014-07-15 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
US20090131479A1 (en) * | 2006-01-06 | 2009-05-21 | Acelrx Pharmaceuticals, Inc. | Small-volume oral transmucosal dosage |
US20100137836A1 (en) * | 2006-01-06 | 2010-06-03 | Acelrx Pharmaceuticals, Inc. | Storage and Dispensing Devices for Administration of Oral Transmucosal Dosage Forms |
US8202535B2 (en) | 2006-01-06 | 2012-06-19 | Acelrx Pharmaceuticals, Inc. | Small-volume oral transmucosal dosage forms |
US8231900B2 (en) | 2006-01-06 | 2012-07-31 | Acelrx Pharmaceutical, Inc. | Small-volume oral transmucosal dosage |
US10709881B2 (en) | 2006-01-06 | 2020-07-14 | Acelrx Pharmaceuticals, Inc. | Apparatus for administering small volume oral transmucosal dosage forms |
US8252328B2 (en) | 2006-01-06 | 2012-08-28 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
US8357114B2 (en) | 2006-01-06 | 2013-01-22 | Acelrx Pharmaceuticals, Inc. | Drug dispensing device with flexible push rod |
US8499966B2 (en) | 2006-01-06 | 2013-08-06 | Acelrx Pharmaceuticals, Inc. | Method of moving a delivery member of a dispensing device for administration of oral transmucosal dosage forms |
US8535714B2 (en) | 2006-01-06 | 2013-09-17 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
US10507180B2 (en) | 2006-01-06 | 2019-12-17 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
US10342762B2 (en) | 2006-01-06 | 2019-07-09 | Acelrx Pharmaceuticals, Inc. | Small-volume oral transmucosal dosage forms |
US10245228B2 (en) | 2006-01-06 | 2019-04-02 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
US8865743B2 (en) | 2006-01-06 | 2014-10-21 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
US8865211B2 (en) | 2006-01-06 | 2014-10-21 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
US8905964B2 (en) | 2006-01-06 | 2014-12-09 | Acelrx Pharmaceuticals, Inc. | Drug storage and dispensing devices and systems comprising the same |
US9744129B2 (en) | 2006-01-06 | 2017-08-29 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
US9642996B2 (en) | 2006-01-06 | 2017-05-09 | Acelrx Pharmaceuticals, Inc. | Methods and apparatus for administering small volume oral transmucosal dosage forms |
US8778394B2 (en) | 2006-01-06 | 2014-07-15 | Acelrx Pharmaceuticals, Inc. | Small-volume oral transmucosal dosage forms |
US9320710B2 (en) | 2006-01-06 | 2016-04-26 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
US20070260491A1 (en) * | 2006-05-08 | 2007-11-08 | Pamela Palmer | System for delivery and monitoring of administration of controlled substances |
US20070299687A1 (en) * | 2006-06-23 | 2007-12-27 | Pamela Palmer | Inpatient system for patient-controlled delivery of oral transmucosal medications dosed as needed |
US9066847B2 (en) | 2007-01-05 | 2015-06-30 | Aceirx Pharmaceuticals, Inc. | Storage and dispensing devices for administration of oral transmucosal dosage forms |
US8252329B2 (en) | 2007-01-05 | 2012-08-28 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
US20080164275A1 (en) * | 2007-01-05 | 2008-07-10 | Acelrx Pharmaceuticals, Inc. | Storage and dispensing devices for administration of oral transmucosal dosage forms |
US8945592B2 (en) | 2008-11-21 | 2015-02-03 | Acelrx Pharmaceuticals, Inc. | Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same |
US11058856B2 (en) | 2014-12-23 | 2021-07-13 | Acelrx Pharmaceuticals, Inc. | Systems, devices and methods for dispensing oral transmucosal dosage forms |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070020186A1 (en) | Solid dosage formulations of narcotic drugs having improved buccal adsorption | |
Hussain et al. | Improved buccal delivery of opioid analgesics and antagonists with bitterless prodrugs | |
US6680071B1 (en) | Opioid agonist in a fast dispersing dosage form | |
KR101545874B1 (ko) | 난용성 약물의 전달을 위한 입상 조성물 | |
ES2439581T3 (es) | Nueva composición farmacéutica no susceptible de abuso que comprende opioides | |
AU774175B2 (en) | Pharmaceutical formulations and methods comprising intranasal morphine | |
US20090263476A1 (en) | Composition of Rapid Disintegrating Direct Compression Buccal Tablet | |
US20130095174A1 (en) | Compositions and Methods for Transmucosal Delivery of Lofexidine | |
CH708257B1 (de) | Zusammensetzung zur Behandlung einer Opioid-induzierten unerwünschten pharmakodynamischen Reaktion. | |
EP2983719A1 (en) | Manufacturing process for effervescent dosage forms | |
US20080125453A1 (en) | Phenylephrine tannate, pyrilamine tannate and dextromethorphan tannate salts in pharmaceutical compositions | |
US10874658B2 (en) | Sublingual opioid formulations containing naloxone | |
US6264974B1 (en) | Buccal and sublingual administration of physostigmine | |
JP2001131068A (ja) | エナラプリル塩を安定化した製剤及びその方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ALPEX PHARMA S.A., SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:STROPPOLO, FEDERICO;ARDALAN, SHAHBAZ;REEL/FRAME:016897/0546 Effective date: 20050909 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |